Texas Dermatology and Laser Specialists | San Antonio, Texas
Status and phase
Conditions
Treatments
About
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
All Participants
Additional Inclusion Criteria for Participants With Normal Hepatic Function
Additional Inclusion Criteria for Participants With Hepatic Impairment - Participants with stable hepatic impairment that meets the criteria for Class A, Class B, or Class C of the modified Child-Pugh Classification. Stable hepatic disease defined as no clinically significant change in disease status in the last 28 days prior to the screening visit.
Key Exclusion Criteria:
For All Participants
Any condition or surgery that could possibly affect drug absorption, including, but not limited to, bowel resections, bariatric weight loss surgery/procedures, gastrectomy, and cholecystectomy.
Receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination or booster within 7 days of planned dosing.
Have recently been diagnosed with symptomatic coronavirus disease 2019 (COVID-19) or test positive for SARS-CoV-2 within 15 days prior to signing the informed consent form (ICF).
Positive drug screen or a positive test for alcohol at Screening or Baseline (Check-in/Day -1) Visits.
Use of prohibited medications prior to randomization or likely to require prohibited concomitant therapy during the trial.
Current use of tobacco or nicotine-containing products (cigarettes, cigars, chewing tobacco, snuff, e-cigarettes, etc). Note: Light smokers (<5 cigarettes/day or equivalent) are allowed provided they abstain from the use of tobacco- or nicotine-containing products for at least 2 hours prior to PK assessments.
Known allergy or hypersensitivity to the investigational medicinal product (IMP), closely related compounds, or any of their specified ingredients.
Has received IMP in a clinical trial of emraclidine within 12 months of signing the ICF.
Participants with a 12-lead ECG demonstrating any of the following at the Screening Visit and at Check-in (Day -1):
Blood pressure measurements demonstrating any of the following at the Screening Visit and/or at Check-in (Day -1):
Additional Exclusion Criteria for Participants with Hepatic Impairment
Primary purpose
Allocation
Interventional model
Masking
40 participants in 4 patient groups
Loading...
Central trial contact
María Inés Enei
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal